Patent · US Active

Poxviral vectors for low antibody response after a first priming immunization

US10111946B2 · kind B2 · utility

0Cited by

3References

17Claims

0Family size

Assignee

Bavarian Nordic A/S · DK

Inventors

Robin Steigerwald · Munich, DE
Kay Brinkmann · Munich, DE
Ulrike Dirmeier · Starnberg, DE
Paul Chaplin · Munich, DE

Key dates

Filing date	Jun 21, 2013
Grant date	Oct 30, 2018
Priority date	—
Expiry date	Aug 30, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2830/60
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention is drawn to compositions and methods for the induction of an immune response, in particular a strong CD8 T cell response, to a specific antigenic determinant without raising a significant antibody response to the antigenic determinant after a first, priming immunization. The method comprises administering to the host a recombinant poxviral vector comprising a transcriptional control element comprising an early and/or late element linked to a nucleotide sequence encoding the antigenic determinant. The recombinant poxviral vector comprises a transcriptional control element comprising an early and/or late element linked to a nucleotide sequence encoding the antigenic determinant. The late element may be stronger than the cowpox ATI promoter in HeLa cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.